PENIBRIN 1 G

Kraj: Izrael

Język: angielski

Źródło: Ministry of Health

Składnik aktywny:

AMPICILLIN AS SODIUM

Dostępny od:

ABIC MARKETING LTD, ISRAEL

Kod ATC:

J01CA01

Forma farmaceutyczna:

POWDER FOR SOLUTION FOR INJ/INF

Skład:

AMPICILLIN AS SODIUM 1 G/VIAL

Droga podania:

I.M, I.V

Typ recepty:

Required

Wyprodukowano przez:

SANDOZ GmbH, AUSTRIA

Grupa terapeutyczna:

AMPICILLIN

Dziedzina terapeutyczna:

AMPICILLIN

Wskazania:

Penibrin injection is recommended in serious infections when prompt, effective levels of the antibiotic must reach the site of infection. Such infections include meningitis, subacute bacterial endocarditis, peritonitis, septicemia, severe forms of chronic bronchitis, osteomyelitis, pneumonia and pyelonephritis due to susceptible organisms.

Data autoryzacji:

2021-12-31

Ulotka dla pacjenta

[לוגו מדינת ישראל] [http://www.gov.il/]
[http://www.gov.il/] [לוגו משרד הבריאות] [לוגו משרד
הבריאות] [*5400]
[http://www.health.gov.il/PniyotHazibur/Pages/CallCenter.aspx]
[http://www.health.gov.il/PniyotHazibur/Pages/CallCenter.aspx]
הציבור הרחב עסקים ומוסדות עובדים
בבריאות חפש מידע
תפריט *
[סגירה]
סגור *
דף הבית [http://www.health.gov.il/] *
אודות *
אודות המשרד
[http://www.health.gov.il/About/Pages/about_us.aspx] *
תוכנית עבודה
[http://www.health.gov.il/About/Pages/Agenda.aspx] *
תקציב המשרד
[http://www.health.gov.il/About/Pages/budget.aspx] *
תרשים מבנה ארגוני
[http://www.health.gov.il/About/Pages/OrganizationalStructureDiagram.aspx] *
בעלי תפקידים
[http://www.health.gov.il/About/Phonebook/Pages/PhoneBook.aspx] *
יחידות המשרד
[http://www.health.gov.il/UnitsOffice/Pages/UnitsList.aspx] *
לשכות הבריאות
[http://www.health.gov.il/About/Phonebook/Pages/PhoneBook.aspx?tab=3] *
אמנת שירות
[http://www.health.gov.il/About/sla/Pages/default.aspx] *
אותות ופרסים
[http://www.health.gov.il/About/Awards/Pages/mifal.aspx] *
פרוייקטים תשתיתיים
[http://www.health.gov.il/About/projects/shared_medical_info/Pages/default.aspx] *
דרושים
[http://www.health.gov.il/About/Careers/Pages/default.aspx] *
מנכ"לי משרד הבריאות לדורותיהם
[http://www.health.gov.il/About/Pages/GeneralManegerHistory.aspx] *
יחידות המשרד *
יחידות המשרד
[http://www.health.gov.il/UnitsOffice/Pages/UnitsList.aspx] *
לשכות הבריאות
[http://www.health.gov.il/UnitsOffice/LB/Pages/default.aspx] *
וועדות ומועצות
[http://www.health.gov.il/Services/Committee/Pages/CommitteeList.aspx] *
נושאים *
בריאות הנפש
[http://www.health.gov.il/Subjects/mental_health/Pages/default.aspx] *
בריאות הסביבה
[http://www.health.gov.il/Subjects/Environmental_Health/

Charakterystyka produktu

SUMMARY OF PRODUCT
CHARACTERISTICS
PENIBRIN
® 500 MG
PENIBRIN
® 1 G
PENIBRIN
® 2 G
POWDER FOR SOLUTION FOR INJECTION/INFUSION
FOR I.M. OR I.V. INJECTION
1.
NAME OF THE MEDICINAL PRODUCT
PENIBRIN
®
500 mg
PENIBRIN
®
1 g
PENIBRIN
®
2 g
2.
QUALITATIVE AND QUANTITATIVE
COMPOSITION
PENIBRIN 500 MG:
One vial contains 531.4 mg of ampicillin sodium
(equivalent to 500 mg ampicillin).
PENIBRIN 1 G:
One vial contains 1063 mg of ampicillin sodium
(equivalent to 1000 mg ampicillin).
PENIBRIN 2 G:
One vial contains 2126 mg of ampicillin sodium
(equivalent to 2000 mg ampicillin).
Excipient with known effect:
PENIBRIN 500 MG: Each vial contains approximately
33 mg sodium.
PENIBRIN 1 G: Each vial contains approximately
66 mg sodium.
PENIBRIN 2 G: Each vial contains approximately
132 mg sodium.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Powder for solution for injection/infusion.
White to off-white powder.
4.
CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
Penibrin injection is recommended in serious
infections when prompt, effective levels of the
antibiotic must reach the site of infection. Such
infections include meningitis, subacute bacterial
endocarditis, peritonitis, septicemia, severe forms
of chronic bronchitis, osteomyelitis, pneumonia
and pyelonephritis due to susceptible organisms.
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
_Parenteral drug products should be inspected _
_visually for particulate matter and discoloration, _
_prior to administration, whenever solution and _
_container permit._
The recommended dosages are given below:
In stubborn, severe infections, a higher dosage
may be administered.
_Adults_
250-500 mg every 6 hours, by intramuscular or
intravenous injection.
_Gonorrhea_
2 doses of 500 mg spaced 12 hours apart. Treatment
may be repeated if necessary.
_Children_
12.5 mg/kg body weight every 6 hours, by
intramuscular or intravenous injection.
_NOTE:_ Larger doses may be required for stubborn or
severe infections. The children’s dosage is intended
for individuals whose